[144] United Therapeutics Corp SEC Filing

Rhea-AI Filing Summary

United Therapeutics Corp. (UTHR) – Form 144 filing. Director-level insider Paul Mahon has filed to sell an additional 11,000 common shares on or about 24 Jul 2025 through Morgan Stanley Smith Barney. At the indicated market value of $3.35 million, the block equals roughly 0.024 % of the 45.1 million shares outstanding.

The filing also discloses recent insider dispositions totaling 66,000 shares over the past three months, generating $19.56 million in gross proceeds. Including the planned sale, Mahon’s cumulative dispositions would reach 77,000 shares, or ~0.17 % of shares outstanding. All shares derive from stock-option exercises paid in cash.

No company financials are provided; the document is strictly a notice required by Rule 144. While the absolute share count is modest, continued insider selling may attract investor attention. The filing confirms regulatory compliance and does not assert possession of undisclosed adverse information.

Positive

• Regulatory compliance: Filing under Rule 144 signals adherence to disclosure requirements, mitigating legal risk.

Negative

• Continued insider selling: Aggregate 77,000 shares scheduled or sold in three months may be perceived as a bearish sentiment indicator.
• Lack of offsetting insider buys: No purchases disclosed to counterbalance the disposals.

Insights

Securities Analyst

TL;DR: Small—0.024 %—insider sale; ongoing disposals worth $23 m YTD could be viewed as mild negative but not financially material.

The proposed 11,000-share sale adds to a 66,000-share disposal history over the last quarter. Even combined, the 77,000 shares equal just 0.17 % of UTHR’s float, limiting dilution or ownership impact. Insider sales may hint at reduced personal conviction, yet the transactions stem from option exercises, a common liquidity event. No operational data accompany the notice, so fundamental outlook remains unchanged. Overall impact: neutral-to-slightly negative; likely minimal share-price effect absent broader context.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	11000	3345224.30	45106623	07/24/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/24/2025	Stock Option Exercise	Issuer			11000	07/24/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	07/10/2025	11000	3303393.50
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	06/26/2025	11000	3142717.60
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	06/12/2025	11000	3079513.80
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	05/29/2025	4000	1263080.00
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	05/29/2025	7000	2213684.90
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	05/15/2025	11000	3246149.50
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	05/01/2025	11000	3310200.30

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many United Therapeutics (UTHR) shares are being sold under this Form 144?

11,000 common shares are slated for sale.

What is the estimated market value of the planned UTHR share sale?

Approximately $3.35 million based on the filing’s stated price.

How significant is the sale relative to shares outstanding?

The block equals about 0.024 % of the 45.1 million shares outstanding, a minor portion of float.

Have there been other recent insider sales by the same filer?

Yes. Mahon has already sold 66,000 shares since May 2025, generating roughly $19.56 million in proceeds.

What is the nature of the shares being sold?

All shares originate from stock-option exercises paid for in cash.

Which broker is handling the transaction?

Morgan Stanley Smith Barney LLC, Executive Financial Services desk.